化肝纤方治疗乙肝肝硬化代偿期瘀血阻络证疗效机制理论探讨OA
Theoretical Discussion on the Therapeutic Mechanism of Huaganxian Prescription in the Treatment of Blood Stasis Obstructing Collaterals Pattern of Compensated HBV-related Cirrhosis
从乙肝肝硬化病因病机、化肝纤方的基本方义、药物成分药理研究及临床疗效等方面探讨化肝纤方治疗乙肝肝硬化代偿期瘀血阻络证的疗效机制,指出化肝纤方基于中医中药理论,采用活血祛瘀、益气散结的治疗法则,结合中药药理与临床经验进行化裁,用药精当,配伍严谨,契合乙肝肝硬化代偿期湿毒损伤肝脏,阻滞气机,瘀血渐生阻滞肝络的病理机制.且化肝纤方具有减少细胞外基质生成、抑制肝纤维化、保护肝脏、抗炎、抗抑郁等作用机制.
We discussed therapeutic mechanism of Huaganxian(hepatic fibrosis-eliminating)prescription in the treatment of blood stasis obstructing collaterals pattern of compensated HBV-related cirrhosis from the etiology and pathogenesis of the disease,basic meaning of Huaganxian prescription,pharmacological studies of drug components and clinical effects.Huaganxian prescription adopted therapeutic principles of activating blood and removing stasis,benefiting Qi and resolving massed based on TCM theory,modified in light of the pharmacology of TCM and clinical experience,with precision in medication selecton and rigor in formula composi-tion,conforming to the pathogenesis of compensated HBV-related cirrhosis:damp-toxin damaging liver,obstruc-ting Qi movement,and blocking liver collateral by chronic blood stasis.The prescription could reduce the produc-tion of extracellular matrix,inhibit hepatic fibrosis,protect liver,fight against the inflammation and depression.
韦湘红;胡振斌
广西中医药大学,广西 南宁 530000广西中医药大学第一附属医院,广西 南宁 530000
医药卫生
乙肝肝硬化化肝纤方代偿期瘀血阻络证机制探讨
HBV-related cirrhosisHuaganxian prescriptioncompensatory periodblood stasis obstructing collaterals patternmechanism discussion
《西部中医药》 2026 (1)
160-164,5
国家科技重大专项课题(2018ZX10725505-002).
评论